{
  "ticker": "EMD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960363",
  "id": "02960363",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250620",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06ky2812phwtbl.pdf",
  "summary": "**Summary of ASX Announcement for Trading/Capital Markets:**  \n\n- **Key Highlight**: Emyria\u2019s Chief Scientific Officer presenting at Psychedelic Science 2025 (PS25), spotlighting the landmark **Medibank reimbursement agreement** for PTSD treatment.  \n- **Next Catalyst**: Investor webinar on the funding model to be announced next week.  \n\nNo material financial, operational, or capital structure updates identified. Event highlights reinforce strategic positioning but do not directly impact immediate trading decisions.  \n\n*Omitted: Forward-looking statements, regulatory disclaimers, general corporate overview.*",
  "usage": {
    "prompt_tokens": 1565,
    "completion_tokens": 119,
    "total_tokens": 1684,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T23:48:22.565972"
}